These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Identification of a small compound that specifically inhibits Zika virus in vitro and in vivo by targeting the NS2B-NS3 protease. Miao J; Yuan H; Rao J; Zou J; Yang K; Peng G; Cao S; Chen H; Song Y Antiviral Res; 2022 Mar; 199():105255. PubMed ID: 35143853 [TBL] [Abstract][Full Text] [Related]
4. Identification of novel Zika virus NS3 protease inhibitors with different inhibition modes by integrative experimental and computational approaches. Andrade MA; Mottin M; Sousa BKP; Barbosa JARG; Dos Santos Azevedo C; Lasse Silva C; Gonçalves de Andrade M; Motta FN; Maulay-Bailly C; Amand S; Santana JM; Horta Andrade C; Grellier P; Bastos IMD Biochimie; 2023 Sep; 212():143-152. PubMed ID: 37088408 [TBL] [Abstract][Full Text] [Related]
5. NS2B-NS3 protease inhibitors as promising compounds in the development of antivirals against Zika virus: A systematic review. Nunes DAF; Santos FRDS; da Fonseca STD; de Lima WG; Nizer WSDC; Ferreira JMS; de Magalhães JC J Med Virol; 2022 Feb; 94(2):442-453. PubMed ID: 34636434 [TBL] [Abstract][Full Text] [Related]
6. Structure-based discovery of clinically approved drugs as Zika virus NS2B-NS3 protease inhibitors that potently inhibit Zika virus infection in vitro and in vivo. Yuan S; Chan JF; den-Haan H; Chik KK; Zhang AJ; Chan CC; Poon VK; Yip CC; Mak WW; Zhu Z; Zou Z; Tee KM; Cai JP; Chan KH; de la Peña J; Pérez-Sánchez H; Cerón-Carrasco JP; Yuen KY Antiviral Res; 2017 Sep; 145():33-43. PubMed ID: 28712942 [TBL] [Abstract][Full Text] [Related]
7. Identification of Zika virus NS2B-NS3 protease and NS5 polymerase inhibitors by structure-based virtual screening of FDA-approved drugs. Ezzemani W; Altawalah H; Windisch M; Ouladlahsen A; Saile R; Kettani A; Ezzikouri S J Biomol Struct Dyn; 2024 Sep; 42(15):8073-8088. PubMed ID: 37528667 [TBL] [Abstract][Full Text] [Related]
8. Identification of Montelukast as flavivirus NS2B-NS3 protease inhibitor by inverse virtual screening and experimental validation. Jiang H; Zhang Y; Wu Y; Cheng J; Feng S; Wang J; Wang X; Cheng M Biochem Biophys Res Commun; 2022 May; 606():87-93. PubMed ID: 35339757 [TBL] [Abstract][Full Text] [Related]
9. Orthoflaviviral Inhibitors in Clinical Trials, Preclinical In Vivo Efficacy Targeting NS2B-NS3 and Cellular Antiviral Activity via Competitive Protease Inhibition. Cavina L; Bouma MJ; Gironés D; Feiters MC Molecules; 2024 Aug; 29(17):. PubMed ID: 39274895 [TBL] [Abstract][Full Text] [Related]
12. The GA-Hecate Peptide inhibits the ZIKV Replicative Cycle in Different Steps and can Inhibit the Flavivirus NS2B-NS3 Protease after Cell Infection. da Silva Sanches PR; de Campos Faria JCE; Bittar C; Guberovich Olivieri HAS; de Moraes Roso Mesquita NC; Noske GD; de Godoy AS; Oliva G; Rahal P; Cilli EM Protein Pept Lett; 2024; 31(7):532-543. PubMed ID: 39039677 [TBL] [Abstract][Full Text] [Related]
13. Identification of novel small molecule inhibitors against NS2B/NS3 serine protease from Zika virus. Lee H; Ren J; Nocadello S; Rice AJ; Ojeda I; Light S; Minasov G; Vargas J; Nagarathnam D; Anderson WF; Johnson ME Antiviral Res; 2017 Mar; 139():49-58. PubMed ID: 28034741 [TBL] [Abstract][Full Text] [Related]
14. Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction. Li Z; Brecher M; Deng YQ; Zhang J; Sakamuru S; Liu B; Huang R; Koetzner CA; Allen CA; Jones SA; Chen H; Zhang NN; Tian M; Gao F; Lin Q; Banavali N; Zhou J; Boles N; Xia M; Kramer LD; Qin CF; Li H Cell Res; 2017 Aug; 27(8):1046-1064. PubMed ID: 28685770 [TBL] [Abstract][Full Text] [Related]
15. Allosteric Inhibitors of Zika Virus NS2B-NS3 Protease Targeting Protease in "Super-Open" Conformation. Meewan I; Shiryaev SA; Kattoula J; Huang CT; Lin V; Chuang CH; Terskikh AV; Abagyan R Viruses; 2023 Apr; 15(5):. PubMed ID: 37243192 [TBL] [Abstract][Full Text] [Related]
16. Investigating into the molecular interactions of flavonoids targeting NS2B-NS3 protease from ZIKA virus through Yadav R; Selvaraj C; Aarthy M; Kumar P; Kumar A; Singh SK; Giri R J Biomol Struct Dyn; 2021 Jan; 39(1):272-284. PubMed ID: 31920173 [TBL] [Abstract][Full Text] [Related]
17. Allosteric quinoxaline-based inhibitors of the flavivirus NS2B/NS3 protease. Zephyr J; Rao DN; Johnson C; Shaqra AM; Nalivaika EA; Jordan A; Kurt Yilmaz N; Ali A; Schiffer CA Bioorg Chem; 2023 Feb; 131():106269. PubMed ID: 36446201 [TBL] [Abstract][Full Text] [Related]
18. The Inhibition of NS2B/NS3 Protease: A New Therapeutic Opportunity to Treat Dengue and Zika Virus Infection. Starvaggi J; Previti S; Zappalà M; Ettari R Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673962 [TBL] [Abstract][Full Text] [Related]
19. The discovery of Zika virus NS2B-NS3 inhibitors with antiviral activity via an integrated virtual screening approach. Mirza MU; Alanko I; Vanmeert M; Muzzarelli KM; Salo-Ahen OMH; Abdullah I; Kovari IA; Claes S; De Jonghe S; Schols D; Schinazi RF; Kovari LC; Trant JF; Ahmad S; Froeyen M Eur J Pharm Sci; 2022 Aug; 175():106220. PubMed ID: 35618201 [TBL] [Abstract][Full Text] [Related]